Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discusses data from the single-arm Phase II trial (NCT03436862) of nivolumab, an anti-PD-1 monoclonal antibody, as maintenance therapy in patients with Hodgkin lymphoma who have undergone autologous stem cell transplant. Maintenance brentuximab vedotin is currently the standard of care and 37 patients were enrolled in the trial to receive nivolumab. Whilst some patients discontinued treatment due to adverse events, progression-free survival was 92.1% and overall survival was 100% after a 9 month follow-up. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.